ANG II-AT1 receptor pathway is involved in the anti-fibrotic effect of beta-elemene

Rui Zhu1, Ling Yang, Lin Shen

  • 1Department of Traditional Chinese Medicine, Huazhong University of Science and Technology, Wuhan, 430022, China. zhurui19830108@163.com

Insights

Beta-elemene treatment effectively inhibited liver fibrosis progression in rats. This natural compound reduced collagen deposition and suppressed the angiotensin II-AT1 receptor pathway, offering a potential therapeutic strategy for liver fibrosis.

Area of Science:

  • Pharmacology
  • Hepatology
  • Biochemistry

Background:

  • Liver fibrosis is a significant health concern characterized by excessive collagen deposition.
  • The renin-angiotensin system, particularly angiotensin II (ANG II) and its AT1 receptor (AT1R), is implicated in the pathogenesis of liver fibrosis.

Purpose of the Study:

  • To investigate the therapeutic effects of beta-elemene on the ANG II-AT1 receptor pathway in a rat model of carbon tetrachloride (CCl4)-induced liver fibrosis.
  • To determine if beta-elemene can modulate key markers of liver fibrosis and the ANG II-AT1 receptor pathway.

Main Methods:

  • Hepatic fibrosis was induced in Wistar male rats using CCl4.
  • Beta-elemene was administered intraperitoneally for 8 weeks.
  • Liver fibrosis was assessed using Masson staining, hydroxyproline content, and liver function tests.
  • Plasma ANG II levels were measured by radioimmunoassay.
  • Hepatic AT1R expression was quantified using reverse transcriptional-polymerase chain reaction and immunohistochemistry.

Main Results:

  • Beta-elemene administration significantly reduced collagen deposition and inhibited the progression of liver fibrosis.
  • Treatment with beta-elemene led to a decrease in plasma ANG II levels.
  • The expression of hepatic AT1R was suppressed by beta-elemene in fibrotic rat livers.

Conclusions:

  • The ANG II-AT1 receptor pathway plays a crucial role in the development and progression of hepatic fibrosis.
  • Beta-elemene demonstrates antifibrotic effects by down-regulating plasma ANG II levels and hepatic AT1R expression.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...